San Diego, CA, United States of America

Takashi Kiyoizumi


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2008-2011

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Takashi Kiyoizumi

Introduction

Takashi Kiyoizumi is a notable inventor based in San Diego, CA. He has made significant contributions to the field of medicine, particularly in the treatment of gastrointestinal disorders. With a total of 3 patents to his name, Kiyoizumi's work has the potential to impact many lives.

Latest Patents

Kiyoizumi's latest patents focus on innovative methods for treating irritable bowel syndrome and ulcerative colitis. His patent titled "Phenoxyalkylcarboxylic acid derivatives in the treatment of irritable bowel syndrome" outlines a method for administering effective compounds to patients suffering from this condition. Another significant patent, "Phenoxyalkylcarboxylic acid derivatives in the treatment of ulcerative colitis," describes a similar approach for treating patients with ulcerative colitis, emphasizing the importance of effective compounds and their metabolites.

Career Highlights

Kiyoizumi is currently associated with Medicinova, Inc., a company dedicated to developing innovative therapies for various medical conditions. His work at Medicinova has allowed him to focus on groundbreaking research that addresses critical health issues.

Collaborations

Throughout his career, Kiyoizumi has collaborated with esteemed colleagues, including Kenneth Walter Locke and Charles G Smith. These partnerships have fostered an environment of innovation and creativity, leading to advancements in medical treatments.

Conclusion

Takashi Kiyoizumi's contributions to the field of medicine through his patents and collaborations highlight his dedication to improving patient care. His innovative approaches to treating gastrointestinal disorders demonstrate the impact that dedicated inventors can have on healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…